002294SZSE

2025 Annual Report of Independent Director (Liu Laiping)

✨ AI Summary

This report details the performance of Independent Director Liu Laiping in 2025. He attended all 9 board meetings and actively participated in committee work, focusing on financial reporting, internal controls, and director/executive compensation. Liu Laiping confirmed no conflicts of interest and adherence to independence requirements. He will step down in January 2026 after serving six years.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Shenzhen Salubris Pharmaceuticals Co., Ltd.

2025 Annual Report of Independent Director

To all shareholders and shareholder representatives:

As an independent director of Shenzhen Salubris Pharmaceuticals Co., Ltd. (hereinafter referred to as the "Company"), for the year 2025, I have strictly followed the relevant laws and regulations and requirements, diligently exercised my duties as an independent director, and effectively protected the legitimate rights and interests of the Company and all shareholders, especially small and medium shareholders. The report on the fulfillment of my duties in 2025 is as follows:

I. Basic Information

(I) Personal Work Experience, Professional Background, and Concurrent Positions

Liu Laiping, Chinese nationality, no overseas residency, male, born in 1970, holds a Ph.D. in Law. During the reporting period, he served as an independent director of the Company, convener of the Remuneration and Appraisal Committee, member of the Nomination Committee, and member of the Audit Committee.

From July 1993 to May 2003, he served as clerk, acting judge, and judge at the Longgang District People's Court of Shenzhen, and Deputy Director of the Execution Division. From May 2003 to August 2013, he served as acting judge, judge, deputy division chief, division chief, and member of the Judicial Committee at the Intermediate People's Court of Shenzhen. Since 2014, he has served as General Manager of the Legal Affairs Department of Mindray Bio-Medical Electronics Co., Ltd. in China. Since January 2017, he has served as Deputy General Manager of Mindray Medical. From June 2022 to January 2024, he served as a director of Mindray Medical Technology Holdings Co., Ltd. From January 2020 to February 2026, he served as an independent director of Shenzhen Salubris Pharmaceuticals Co., Ltd.

(II) Statement on Whether There Are Any Circumstances Affecting Independence

As an independent director of the Company, after self-examination, during my tenure as an independent director, I have not held any positions in the Company other than independent director, nor have I held any positions in the companies of major shareholders. There are no conflicts of interest between me and the Company or its major shareholders, nor are there any other relationships that may hinder my independent and objective judgment. There are no other circumstances affecting the independence of independent directors. My tenure meets the independence requirements stipulated in the "Administrative Measures for Independent Directors of Listed Companies" and other regulations, and there are no circumstances affecting independence.

II. Annual Performance Overview

(I) In 2025, the Company held 9 board meetings. The attendance details are as follows:

Independent Director NameNumber of Meetings AttendedNumber of On-site AttendanceNumber of Attendance by CommunicationNumber of Attendance by ProxyNumber of AbsencesWhether Consecutive Two Meetings Were Not Attended in Person
Liu Laiping90900No

This year, I attended the board meetings on time, carefully reviewed all proposals, and expressed my independent opinions. There were no dissenting or abstaining votes.

(II) In 2025, the Company held 2 shareholder meetings. I was unable to attend due to official business.

(III) Participation in the Work of Board Special Committees and Independent Director Special Meetings

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.